1. Home
  2. NGNE vs NRIM Comparison

NGNE vs NRIM Comparison

Compare NGNE & NRIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$30.98

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

NRIM

Northrim BanCorp Inc

HOLD

Current Price

$24.89

Market Cap

602.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
NRIM
Founded
2003
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Savings Institutions
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
744.9M
602.6M
IPO Year
2014
2002

Fundamental Metrics

Financial Performance
Metric
NGNE
NRIM
Price
$30.98
$24.89
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$63.57
N/A
AVG Volume (30 Days)
234.1K
106.0K
Earning Date
05-08-2026
04-22-2026
Dividend Yield
N/A
2.62%
EPS Growth
0.93
N/A
EPS
N/A
1.29
Revenue
N/A
$255,581,000.00
Revenue This Year
N/A
$4.98
Revenue Next Year
N/A
$7.40
P/E Ratio
N/A
$19.46
Revenue Growth
N/A
30.43
52 Week Low
$15.93
$19.60
52 Week High
$43.66
$30.82

Technical Indicators

Market Signals
Indicator
NGNE
NRIM
Relative Strength Index (RSI) 41.25 32.82
Support Level $31.20 $24.87
Resistance Level $33.99 $25.32
Average True Range (ATR) 1.95 0.51
MACD -0.47 -0.07
Stochastic Oscillator 20.29 5.73

Price Performance

Historical Comparison
NGNE
NRIM

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About NRIM Northrim BanCorp Inc

Northrim BanCorp Inc is a bank holding company operating through three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. The Community Banking segment, which generates the majority of revenue, provides loan and deposit products to business and consumer customers in its market areas. The Home Mortgage Lending segment focuses on the origination and sale of mortgage loans for one-to-four family residential properties, mortgage loan servicing for certain loans sold, and investment in selected residential mortgage loans. The Specialty Finance segment provides factoring, asset-based lending, and alternative working capital solutions to small and medium-sized enterprises and includes SCF and Northrim Funding Services.

Share on Social Networks: